An Oral Bioactive Chitosan-Decorated Doxorubicin Nanoparticles/bacteria Bioconjugates Enhance Chemotherapy Efficacy in an In-Situ Breast Cancer Model

Breast cancer is the second leading cause of cancer -related deaths among women worldwide. Despite significant advancements in chemotherapy, its effectiveness is often limited by poor drug distribution and systemic toxicity caused by the weak targeting ability of conventional therapeutic agents. The hypoxic tumor microenvironment (TME) also plays a vital role in treatment outcomes. Oral anticancer therapeutic agents have gained popularity and show promising results due to their ease of repeated administration. This study introduces autopilot biohybrids ( Bif @BDC-NPs) for the effective delivery of doxorubicin (DOX) to the tumor site. This hybrid combines albumin -encapsulated DOX nanoparticles (BD -NPs) coated with chitosan (CS) for breast cancer chemotherapy, along with anaerobic Bifidobacterium infantis ( B. infantis , Bif ) serving as self-propelled motors. Due to Bif 's specific anaerobic properties, Bif @BDC-NPs precisely anchor hypoxic regions of tumor tissue and significantly increase drug accumulation at the tumor site, thereby promoting tumor cell death. In an in -situ mouse breast cancer model, Bif @BDC-NPs achieved 94 % tumor inhibition, significantly prolonging the median survival of mice to 62 days, and reducing the toxic side effects of DOX. Therefore, the new bacteria -driven oral drug delivery system, Bif @BDC-NPs, overcomes multiple physiological barriers and holds great potential for the precise treatment of solid tumors.